Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q3 2024 · 10-Q
Revenue$4.35M$4.35M−53.2% vs Q3 2023 Net Income-$7.59M-$7.59MN/M vs Q3 2023 EPS Diluted-$0.11-$0.11N/M vs Q3 2023 Operating Income-$10,471,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$22,000,000N/M Margins · derivedOperating margin-240.9%+99.3 pt vs Q3 2023
Net margin-174.6%+140.7 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 6, 2024 · 37 d after period end